Disclosures for "The Phase 4 OCTAGON Study Investigating Oral Corticosteroid Tapering in Adult Patients with Generalized Myasthenia Gravis Treated with Ravulizumab: Trial in Progress"
-
Dr. Yungher has received personal compensation for serving as an employee of Alexion AstraZeneca Rare Disease.
-
Dr. Weiskopf has received personal compensation for serving as an employee of Alexion AstraZeneca Rare Disease. Dr. Weiskopf has or had stock in Alexion Astrazeneca Rare Disease.
-
Rasha Aguzzi has received personal compensation for serving as an employee of Alexion Pharmaceutical. Rasha Aguzzi has or had stock in AstraZeneca.
-
Guido Sabatella has received personal compensation for serving as an employee of Alexion.